News
06-22-2010, 03:23 AM
Cellceutix Corporation (OTCBB: CTIX) is pleased to announce that they have concluded more pre-clinical cell studies for Kevetrin, their flagship compound for the treatment of multi-drug resistant strains of lung, breast and colon cancers. The research was conducted on drug resistant non-small cell lung carcinoma cells by the Cellceutix research team at a world-renown cancer hospital in Boston...
More... (http://mnt.to/f/3F8Z)
More... (http://mnt.to/f/3F8Z)